Physician profile
Pratima Chalasani
NPI 1477782522
$297.17
in general payments reported to CMS, 2019-2025
9 companies · $67.66 in 2025
The $67.66 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.86 · 2021: $117 · 2023: $15.72 · 2025: $67.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.21 · Education: $14.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.21 |
| Education | $14.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $105.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $54.96 | 2019 | |
| Pfizer INC. | $52.54 | 2019-2025 | |
| Daiichi Sankyo INC. | $28.71 | 2025 | Enhertu |
| Astellas Pharma US INC | $24.78 | 2025 | Vyloy |
| E.R. Squibb & Sons, L.L.C. | $19.25 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratima Chalasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.